Effect Of Baduanjin On Quality Of Life Of Regular Hemodialysis Patients

Objective:By exploring the improvement of Baduanjin on cardiac function level,anemia,and SF-36 quality of life scale and other scale scores of regular hemodialysis patients,the effect of Baduanjin on the quality of life of regular hemodialysis patients was clarified,and the clinical application of Baduanjin Brocade provides theoretical and practical references for the treatment of hemodialysis patients.Methods:The first stage: 120 patients were randomly included in regular hemodialysis treatment according to the nanoscale standard.Based on general conditions questionnaire,cardiac function classification,left ventricular ejection fraction,BNP,hemoglobin and other laboratory indicators,Minnesota quality of life scale,and SF-36 Quality of Life Scale as a research tool to assess the quality of life of included patients;The second stage: 120 patients were randomly divided into a control group and a treatment group,with 60 patients in each group.Among them,the patients in the control group received basic treatment,and the patients in the treatment group were treated with Baduanjin in addition to the basic treatment.The treatment method is 3 times a week,15 minutes each time,fixed at half an hour before dialysis,and intervention treatment for 6months.After the trial,all patients’ cardiac function classification,laboratory observation indicators,and quality of life scale scores were collected.Statistical analysis was performed using SPSS19.0.Results:A total of 120 patients were enrolled.Seven patients fell off during the trial.The number of effective cases was 113,of which there were 57 cases in the control group and 56 cases in the treatment group.Of the 113 patients,36 had normal cardiac function,77 had abnormal cardiac function,30 had central function class I patients,29 had cardiac function class II patients,and 18 had cardiac function class III patients.The results before and aftertreatment are summarized as follows:1.There was no significant difference between the two groups of patients before treatment(including gender,age,duration of disease),cardiac function classification,laboratory indicators,Minnesota quality of life scale and SF-36 quality of life scale score(P> 0.05).,The two groups of patients are comparable.2.Comparison of cardiac function classification between two groups of patients.After treatment,there was no significant change in cardiac function in the control group(P> 0.05),and cardiac function in the treatment group was significantly improved(P <0.05).The group improved significantly(P <0.05).3.Comparison of laboratory indicators between the two groups of patients.After treatment,the left ventricular ejection fraction,BNP,and hemoglobin of the treatment group were improved(P <0.05),and the left ventricular ejection fraction,BNP,and hemoglobin of the treatment group were compared between the groups.The improvement was significantly better than the control group(P <0.05).4.Comparison of changes in the scores of the Minnesota Quality of Life Scale between the two groups of patients.After treatment,the scores of the treatment group were significantly lower than before(P <0.05),and the scores between the treatment groups were significantly lower than those of the control group(P <0.05).The total effective rate 73.2%.5.Comparison of changes in SF-36 quality of life scale scores between the two groups of patients.After treatment,the scores in the treatment group increased significantly(P<0.05),and the scores in the treatment group were significantly higher than those in the control group(P <0.05).The effective rate is 69.6%.6.A total of 3 adverse events occurred during the course of this study,and the incidence of adverse events was 5.4%.7.The re-hospitalization rate of the control group during the study was 42.1%,and the re-hospitalization rate of the treatment group was 23.2%.The difference between the groups was statistically significant(P <0.05).8.During the study,the mortality rate in the control group was 3.5% and the mortalityrate in the treatment group was 1.8%.Conclusion:Experimental studies have shown that Baduanjin is definitely effective for the treatment of RHD patients and can improve the quality of life of RHD patients.details as follows:1 Baduanjin can effectively improve the level of heart function.2 Baduanjin can effectively improve anemia.3 Baduanjin can effectively improve the SF-36 quality of life scale score.4 Baduanjin treatment has a low incidence of adverse reactions and high safety.5 Baduanjin also has certain effects in reducing the rate of rehospitalization and mortality.6 Baduanjin can be used as an important adjuvant therapy on the basis of conventional RHD clinical treatment.